Long-term prognostic role of adiponectin in stable coronary artery disease: A meta-analysis of prospective studies.

IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Sahas Reddy Jitta, Priyanka Vatsavayi, Chenna Reddy Tera, Shobana Krishnamurthy, Saisree Reddy Adla Jala, Diksha Sanjana Pasnoor, Utheja Dasari, Aisha Farooq, Supriya Maramreddy, Kavya Jammula, Medha Reddy Kesani, Sridevi Tripuraneni, Nihar Jena, Rupak Desai
{"title":"Long-term prognostic role of adiponectin in stable coronary artery disease: A meta-analysis of prospective studies.","authors":"Sahas Reddy Jitta, Priyanka Vatsavayi, Chenna Reddy Tera, Shobana Krishnamurthy, Saisree Reddy Adla Jala, Diksha Sanjana Pasnoor, Utheja Dasari, Aisha Farooq, Supriya Maramreddy, Kavya Jammula, Medha Reddy Kesani, Sridevi Tripuraneni, Nihar Jena, Rupak Desai","doi":"10.4330/wjc.v17.i6.105452","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The persistent burden of cardiovascular (CV) disease in the United States requires innovative and cost-effective prognostic markers that can be relied upon.</p><p><strong>Aim: </strong>To provide insights into how adiponectin can predict all-cause mortality and major adverse CV events (MACE) in patients with coronary artery disease (CAD) and to determine the prognostic value of adiponectin in predicting all-cause mortality and MACE in patients with stable CAD.</p><p><strong>Methods: </strong>We conducted a systematic search on PubMed, Scopus, and Google Scholar to find relevant studies published through June 2023 evaluating the long-term prognostic role of adiponectin in patients with stable CAD. Using a random effects model with 95%CI, we estimated the odds ratio (OR) while assessing heterogeneity through <i>I²</i> statistics. To ensure robustness, we performed a sensitivity analysis using the leave-one-out approach.</p><p><strong>Results: </strong>After screening, we included five prospective studies involving 3225 patients who were followed up for a median duration of 3.8 years. Within the study population, prevalent risk factors included hypertension, diabetes, hyperlipidemia, and smoking. The commonly prescribed medications were angiotensin-converting enzyme inhibitors, beta blockers, and statins. The combined adjusted OR for all-cause mortality was found to be 2.51 (95%CI: 1.36-4.62), showing heterogeneity (<i>I²</i> = 65.51%, <i>P</i> = 0.03). On the other hand, the combined adjusted OR for MACE was determined to be 1.04 (95%CI: 1.02-1.06) with no significant heterogeneity observed (<i>I²</i> = 0%, <i>P</i> = 0.68). Through a sensitivity analysis, it was discovered that none of the studies significantly impacted the overall results of the meta-analysis, thus indicating their robustness.</p><p><strong>Conclusion: </strong>Higher levels of adiponectin were found to be associated with an increased risk of long-term mortality and MACE in patients with CAD, which highlights its potential as a cost-effective marker for risk assessment and guiding treatment strategies. Further research on the role of adiponectin could greatly influence decision-making and resource allocation in CV care.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 6","pages":"105452"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12186166/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4330/wjc.v17.i6.105452","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The persistent burden of cardiovascular (CV) disease in the United States requires innovative and cost-effective prognostic markers that can be relied upon.

Aim: To provide insights into how adiponectin can predict all-cause mortality and major adverse CV events (MACE) in patients with coronary artery disease (CAD) and to determine the prognostic value of adiponectin in predicting all-cause mortality and MACE in patients with stable CAD.

Methods: We conducted a systematic search on PubMed, Scopus, and Google Scholar to find relevant studies published through June 2023 evaluating the long-term prognostic role of adiponectin in patients with stable CAD. Using a random effects model with 95%CI, we estimated the odds ratio (OR) while assessing heterogeneity through statistics. To ensure robustness, we performed a sensitivity analysis using the leave-one-out approach.

Results: After screening, we included five prospective studies involving 3225 patients who were followed up for a median duration of 3.8 years. Within the study population, prevalent risk factors included hypertension, diabetes, hyperlipidemia, and smoking. The commonly prescribed medications were angiotensin-converting enzyme inhibitors, beta blockers, and statins. The combined adjusted OR for all-cause mortality was found to be 2.51 (95%CI: 1.36-4.62), showing heterogeneity ( = 65.51%, P = 0.03). On the other hand, the combined adjusted OR for MACE was determined to be 1.04 (95%CI: 1.02-1.06) with no significant heterogeneity observed ( = 0%, P = 0.68). Through a sensitivity analysis, it was discovered that none of the studies significantly impacted the overall results of the meta-analysis, thus indicating their robustness.

Conclusion: Higher levels of adiponectin were found to be associated with an increased risk of long-term mortality and MACE in patients with CAD, which highlights its potential as a cost-effective marker for risk assessment and guiding treatment strategies. Further research on the role of adiponectin could greatly influence decision-making and resource allocation in CV care.

脂联素在稳定型冠状动脉疾病中的长期预后作用:前瞻性研究的荟萃分析
背景:美国心血管(CV)疾病的持续负担需要可依赖的创新和具有成本效益的预后标志物。目的:了解脂联素如何预测冠心病(CAD)患者的全因死亡率和主要不良CV事件(MACE),并确定脂联素在预测稳定型CAD患者的全因死亡率和MACE中的预后价值。方法:我们对PubMed、Scopus和谷歌Scholar进行了系统检索,找到截至2023年6月发表的相关研究,评估脂联素在稳定型CAD患者中的长期预后作用。使用95%CI的随机效应模型,我们通过I²统计量评估异质性时估计了优势比(OR)。为了确保稳健性,我们使用留一方法进行了敏感性分析。结果:筛选后,我们纳入了5项前瞻性研究,涉及3225例患者,随访时间中位数为3.8年。在研究人群中,流行的危险因素包括高血压、糖尿病、高脂血症和吸烟。常用的处方药物是血管紧张素转换酶抑制剂、受体阻滞剂和他汀类药物。全因死亡率的综合校正OR为2.51 (95%CI: 1.36-4.62),存在异质性(I²= 65.51%,P = 0.03)。另一方面,MACE的综合校正OR为1.04 (95%CI: 1.02-1.06),未观察到显著异质性(I²= 0%,P = 0.68)。通过敏感性分析,发现没有一项研究显著影响meta分析的整体结果,表明其稳健性。结论:高水平的脂联素与冠心病患者长期死亡和MACE风险增加有关,这突出了其作为风险评估和指导治疗策略的成本效益指标的潜力。进一步研究脂联素的作用可能会极大地影响心血管护理的决策和资源分配。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
World Journal of Cardiology
World Journal of Cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
3.30
自引率
5.30%
发文量
54
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信